Kiniksa Pharmaceuticals International, plc (KNSA)

KNSA Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	59.01	-43.19	14.08	183.36	-157.92
Depreciation & Amortization	1.55	1.7	2.34	2.4	2.36
Stock-Based Compensation	37	30.69	27.15	25.12	25.17
Other Adjustments	15.63	11.69	2.17	-182.5	3.41
Change in Receivables	-2.71	26.13	-20.46	-8.68	-3.91
Changes in Inventories	-28.53	4.76	-9.52	-17.92	-3.68
Changes in Accounts Payable	0.14	-6.31	0.35	6.03	1.37
Changes in Accrued Expenses	37.5	43.73	16.94	-3.71	10.34
Changes in Unearned Revenue	19.55	0.26	16.7	12	-
Changes in Other Operating Activities	-25.04	-27.51	-26.37	-10.3	-3.43
Operating Cash Flow	137.99	25.69	13.3	5.81	-126.3
Operating Cash Flow Growth	437.14%	93.14%	129.05%	-	-
Capital Expenditures	-1.57	-0.28	-0.13	-0.11	-0.42
Sale of Property, Plant & Equipment	-	0.03	-	0.09	-
Purchases of Intangible Assets	-	-	-	-	-20
Purchases of Investments	-386.92	-202.01	-204.93	-135.86	-157.25
Proceeds from Sale of Investments	199.49	239.94	175.51	127.8	306.3
Investing Cash Flow	-188.99	37.67	-29.56	-8.08	128.64
Issuance of Common Stock	40.75	17.25	3.7	3.42	5.89
Repurchase of Common Stock	-7.73	-4.98	-2.21	-0.9	-
Net Common Stock Issued (Repurchased)	33.02	12.27	1.5	2.52	5.89
Financing Cash Flow	33.02	12.27	1.5	2.52	5.89
Net Cash Flow	-17.99	75.63	-14.76	0.25	8.22
Free Cash Flow	136.42	25.41	13.17	5.7	-126.71
Free Cash Flow Growth	436.82%	92.94%	130.99%	-	-
FCF Margin	20.13%	6.00%	4.87%	2.59%	-328.75%
Free Cash Flow Per Share	1.73	0.36	0.18	0.08	-1.85
Levered Free Cash Flow	62.61	-26.85	14.39	171.76	-151.39
Unlevered Free Cash Flow	106.78	-20.39	-71.4	-154.58	-148.71

Updated Feb 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q